ERBB2 and colorectal carcinoma: Additionally, CTCs have also been used as a vehicle to assess genotyping changes in primary tumor and metastatic lesions; this is relevant for patients for whom a targeted therapy against known resistance-causing mutations is available, such as HER2-directed treatment for GC and EGFR-directed treatment for CRC (14).